T1	Participants 84 144	patients with anterior tongue and floor of the mouth cancers
T2	Participants 247 294	one-third of the patients received chemotherapy
T3	Participants 417 498	one-third of the patients received immunotherapy with weekly C. parvum injections
T4	Participants 788 833	Patients who previously received radiotherapy
